27 August 2010
Firm develops first ever digital device for collapsed lung aspiration, [...]
20 August 2010
Recent collaboration with Tufts University students and Cambridge Consultants offers [...]
16 August 2010
Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase (CDK) inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
Subscribe to our News RSS Feed
Founded in 1970 by
27 August 2010
Breathe™ easy: Cambridge Consultants technology adds intelligence and automation to aspiration procedures
Firm develops first ever digital device for collapsed lung aspiration, [...]
20 August 2010
Putting the patient first: students work with elderly to define the next stage of the connected health revolution
Recent collaboration with Tufts University students and Cambridge Consultants offers [...]
16 August 2010
Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma
Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase (CDK) inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).